Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

UNKNOWN × Head and Neck Neoplasms × anlotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Nasopharyngeal Carcinoma 1 Head and Neck Neoplasms 1 Breast Neoplasms 1

Interventions

pembrolizumab 2 anlotinib 1 Ondansetron 1 Dexamethasone 1 Aprepitant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04999800 2021-08-11

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

ChineseAMS

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡